The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Public ClinicalTrials.gov record NCT04136366. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferative Vitreoretinopathy
Study identification
- NCT ID
- NCT04136366
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Interventions
- ADX-2191 (intravitreal methotrexate 0.8%) Drug
- Standard surgical care procedure Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2019
- Primary completion
- Jun 13, 2022
- Completion
- Jun 13, 2022
- Last update posted
- Jul 8, 2025
2019 – 2022
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retinal Consultants of Arizona | Phoenix | Arizona | 85053 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Florida Retina Institute | Orlando | Florida | 32806 | — |
| Bascom Palmer Eye Institute | Palm Beach Gardens | Florida | 33418 | — |
| Emory Eye Center | Atlanta | Georgia | 30322 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Illinois Retina Associates | Joliet | Illinois | 60435 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| Massachusetts Eye and Ear | Boston | Massachusetts | 02214 | — |
| New England Retina Consultants | Springfield | Massachusetts | 01107 | — |
| Kresge Eye Institute | Detroit | Michigan | 48201 | — |
| Associated Retinal Consultants | Royal Oak | Michigan | 48073 | — |
| Vitreo-Retinal Surgery | Minneapolis | Minnesota | 55432 | — |
| Mayo Clinic Ophthalmology | Rochester | Minnesota | 55905 | — |
| The Retina Institute | St Louis | Missouri | 63128 | — |
| Long Island VitreoRetinal Consultants | Forest Hills | New York | 11375 | — |
| Duke Health Center | Durham | North Carolina | 27705 | — |
| OHSU Casey Eye Institute | Portland | Oregon | 97239 | — |
| Mid Atlantic Retina | Philadelphia | Pennsylvania | 19107 | — |
| Retina Consultants of Houston | Houston | Texas | 77030 | — |
| University of Washington | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04136366, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04136366 live on ClinicalTrials.gov.